Tackling diversity in prostate cancer clinical trials: A report from the diversity working group of the IRONMAN registry

Rana R. McKay, Theresa Gold, Jelani C. Zarif, Ilkania M. Chowdhury-Paulino, Adam Friedant, Travis Gerke, Marie Grant, Kelly Hawthorne, Elisabeth I. Heath, Franklin W. Huang, Maria Jackson, Brandon Mahal, Osarenren Ogbeide, Kellie Paich, Camille Ragin, Emily M. Rencsok, Stacey Simmons, Clayton Yates, Jacob Vinson, Philip W. KantoffDaniel J. George, Lorelei A. Mucci

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Prostate cancer disproportionately affects racial and ethnic minority populations. Reasons for disparate outcomes among minority patients are multifaceted and complex, involving factors at the patient, provider, and system levels. Although advancements in our understanding of disease biology have led to novel therapeutics for men with advanced prostate cancer, including the introduction of biomarker-driven therapeutics, pivotal translational studies and clinical trials are underrepresented by minority populations. Despite attempts to bridge the disparities gap, there remains an unmet need to expand minority engagement and participation in clinical trials to better define the impact of therapy on efficacy outcomes, quality of life, and role of biomarkers in diverse patient populations. The IRONMAN registry (ClinicalTrials.gov identifier: NCT03151629), a global, prospective, population-based study, was borne from this unmet medical need to address persistent gaps in our knowledge of advanced prostate cancer. Through integrated collection of clinical outcomes, patient-reported outcomes, epidemiologic data, and biospecimens, IRONMAN has the goal of expanding our understanding of how and why prostate cancer outcomes differ by race and ethnicity. To this end, the Diversity Working Group of the IRONMAN registry has developed informed strategies for site selection, recruitment, engagement and retention, and trial design and eligibility criteria to ensure broad inclusion and needs awareness of minority participants. In concert with systematic strategies to tackle the complex levels of disparate care, our ultimate goal is to expand minority engagement in clinical research and bridge the disparities gap in prostate cancer care.

Original languageEnglish
Pages (from-to)495-505
Number of pages11
JournalJCO Global Oncology
Volume7
Issue number7
DOIs
StatePublished - Apr 2021

Keywords

  • Clinical Trials as Topic
  • Ethnicity
  • Humans
  • Male
  • Minority Groups
  • Prospective Studies
  • Prostatic Neoplasms/therapy
  • Quality of Life
  • Registries

Fingerprint

Dive into the research topics of 'Tackling diversity in prostate cancer clinical trials: A report from the diversity working group of the IRONMAN registry'. Together they form a unique fingerprint.

Cite this